White House Expands Ibogaine Research for PTSD Treatment

Got story updates? Submit your updates here. ›

The White House is preparing an executive order to expand federal research into ibogaine, a psychedelic drug used in some countries to treat PTSD. The order is intended to support studies evaluating ibogaine's potential use for post-traumatic stress disorder and traumatic brain injuries, particularly among veterans, though the drug will remain classified as a Schedule I substance for the time being.

Why it matters

Evidence on ibogaine's efficacy remains limited, with concerns about heart toxicity and risk of death. However, the administration sees potential benefits for veterans and others suffering from PTSD and is aiming to further study the drug's therapeutic applications.

The details

The Trump administration plans to keep ibogaine classified as a Schedule I substance and does not intend to approve it for medical use at this time. The order is intended to 'open the door' to federal funding by supporting studies evaluating ibogaine's potential use for post-traumatic stress disorder and traumatic brain injuries, particularly among veterans. A 2023 review of 24 studies including 705 people found reductions in withdrawal symptoms and cravings, but also identified concerns about heart toxicity and risk of death, with at least 27 deaths linked to ibogaine use. Clinical research is still developing, with only one double-blind, placebo-controlled randomized clinical trial being completed so far.

• The White House is expected to sign the executive order as soon as this week.
• The Becker's Fall Behavioral Health Summit, where behavioral health leaders and executives will explore strategies for expanding access to care, is taking place November 4–5 in Chicago.

What’s next

Several states are funding their own research programs and clinical trials on the drug, which could provide additional data to inform the federal government's approach.